# US 2012/0269736 A1 · Micellar compositions for use in biological applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0269736 A1
- Document ID: US20120269736A1
- Status: Published application
- Kind: A1
- Application number: 13/499,098
- Filed: 2010-09-28
- Published: 2012-10-25
- Earliest claimed: 2009-09-29
- Assignees: King's College London
- Inventors: Mark Green; Philip Howes
- Web page: https://patentgrep.com/patent/US20120269736A1

## CPC

- G01N 33/586: {Liposomes, microcapsules or cells}
- A61K 49/0002: {General or multifunctional contrast agents, e.g. chelated agents}
- A61K 49/0019: {characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules}
- A61K 49/0054: {Macromolecular compounds, i.e. oligomers, polymers, dendrimers}
- A61K 49/0082: {micelle, e.g. phospholipidic micelle and polymeric micelle}
- A61K 49/1806: {Suspensions, emulsions, colloids, dispersions}
- A61K 49/1818: {particles, e.g. uncoated or non-functionalised microparticles or nanoparticles}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A composition comprising:
a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum;
a biocompatible surfactant and/or lipid; and
a MRI active agent.

### Claim 31 (depends on 30)

The composition according to claim 30, wherein the composition comprises more than one substantially water-insoluble conjugated polymer.

### Claim 32 (depends on 30)

The composition according to claim 30, wherein the substantially water-insoluble conjugated polymer is selected from:
Poly[9,9-di(3′,7′-dimethyloctyl)fluoren-2,7-yleneethynylene],
Poly[9,9-didodecylfluroenyl-2,7-yleneethylnylene],
Poly[9,9-di(2′-ethylhexyl)fluoren-2,7-yleneethynylene],
Poly(9,9-dioctylfluorenyl-2,7-yleneethynylene),
Poly[9,9-bis-(2-ethylhexyl)-9H-fluorene-2,7-diyl],
Poly(9,9-dihexyl-9H-fluorene-2,7-diyl),
Poly(9,9-di-(2-ethylhexyl)-9H-fluorene-2,7-diyl),
Poly[(9,9-di-(2-ethylhexyl)-9H-fluorene-2,7-diyl)-co-(1-methoxy-4-(2-ethylhexyloxy)-2,5-phenylenevinylene)],
Poly[(9,9-dihexyl-9H-fluorene-2,7-diyl)-co-(1-methoxy-4-(2-ethylhexyloxy)-2,5-phenylenevinylene)],
Poly(2,5-bis(1,4,7,10-tetraoxaundecyl)-1,4-phenylenevinylene),
Poly(2,5-dioctyl-1,4-phenylenevinylene),
Poly(2,5-dioctylphenylene-1,4-ethynylene),
Poly[1,2-bis(benzylthio)acetylene],
Poly[1,2-bis(ethylthio)acetylene],
Poly[bis(methylthio)acetylene],
Poly(3,5 pyridine),
Poly(3-(2-methoxyethoxy)ethoxymethylthiophene-2,5-diyl),
5,5′-Dibromo-2,2′-bithiophene,
Poly(3-butylthiophene-2,5-diyl),
Poly(3-cyclohexyl-4-methylthiophene-2,5-diyl),
Poly(3-cyclohexylthiophene-2,5-diyl),
Poly(3-decylthiophene-2,5-diyl),
Poly(3-dodecylthiophene-2,5-diyl),
Poly(3-hexylthiophene-2,5-diyl),
Poly(3-octylthiophene-2,5-diyl),
Thiophene Oligothiophenes,
5,5′-Dibromo-2,2′-bithiophene,
2,2′,5′,2″,5″,2″′-Quaterthiophene,
α-Sexithiophene,
311073 2,2′:5′,2″-Terthiophene,
Poly(thiophene-2,5-diyl), bromine terminated powder,
2,3-Dihydrothieno[3,4-b]-1,4-dioxin,
3,2′:5′,3″-Terthiophene,
5-Hexyl-2,2′-bithiophene,
22,2′-Bithiophene,
Thiophene,
5,5″″-Dihexyl-2,2′:5′,2″:5″,2″′:5″′,2″″:5″″,2″″′-sexithiophene,
Poly(styrenesulfonate)/poly(2,3-dihydrothieno(3,4-b)-1,4-dioxin),
Poly(3,4-ethylendioxythiophene)-poly(styrenesulfonate),
Poly(3,4-ethylenedioxythiophene)-block-poly(ethylene glycol),
Poly(3,4-ethylenedioxythiophene), tetramethacrylate end-capped,
Poly((9,9-dihexyl-9H-fluorene-2,7-diyl)-co-(1-methoxy-4-(2-ethylhexyloxy)-2,5 -phenylenevinylene)),
Poly((9,9-dihexyl-9H-fluorene-2,7-diyl)-co-(1-methoxy-4-(2-ethylhexyloxy)-2,5 -phenylenevinylene),
Poly(1-methoxy-4-(3-propyloxy-heptaisobutyl-PSS)-2,5-phenylenevinylene)-co-(1-methoxy-4-(2-ethylhexyloxy)-2,5 -phenylenevinylene),
Poly(2,5-bis(3-sulfonatopropoxy)-1,4-phenylene, disodium salt-alt-1,4-phenylene),
Poly(2,5-dihexyloxy-1,4-phenylenevinylene),
Poly(2,5-dioctyl-1,4-phenylenevinylene),
Poly(2,6-naphthalenevinylene),
Poly[5-methoxy-2-(3-sulfopropoxy)-1,4-phenylenevinylene] Potassium salt,
Poly(p-xylene tetrahydrothiophenium chloride),
Poly[(m-phenylenevinylene)-alt-(2-methoxy-5-octyloxy-p-phenylenevinylene)],
Poly[(m-phenylenevinylene)-alt-(2,5-dihexyloxy-p-phenylenevinylene)],
Poly[(m-phenylenevinylene)-alt-(2-methoxy-5-(2-ethylhexyloxy)-p-phenylenevinylene)],
Poly[(m-phenylenevinylene)-co-(2,5-dioctoxy-p-phenylenevinylene)],
Poly[(m-phenylenevinylene)-alt-(2,5-dibutoxy-p-phenylenevinylene)],
Poly[(o-phenylenevinylene)-alt-(2-methoxy-5-(2-ethylhexyloxy)-p-phenylenevinylene)],
Poly[(p-phenylenevinylene)-alt-(2-methoxy-5-(2-ethylhexyloxy)-p-phenylenevinylene)],
Poly[2-(2′,5′-bis(2″-ethylhexyloxy)phenyl)-1,4-phenylenevinylene],
Poly[2,5-bis(3′,7′-dimethyloctyloxy)-1,4-phenylenevinylene],
Poly[(2,5-bisoctyloxy)-1,4-phenylenevinylene],
Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene],
Poly[2-methoxy-5-(3′,7′-dimethyloctyloxy)-1,4-phenylenevinylene],
Poly[5-methoxy-2-(3-sulfopropoxy)-1,4-phenylenevinylene],
Poly[9-(2-ethylhexyl)-3,6-carbazolevinylene-alt-2,6-naphthalenevinylene],
Poly{[2-[2′,5′-bis(2″-ethylhexyloxy)phenyl]-1,4-phenylenevinylene]-co-[2-methoxy-5-(2′-ethylhexyloxy)-1,4-phenylenevinylene]}, and
a combination or any two or more thereof.

### Claim 33 (depends on 32)

The composition according to claim 32, wherein the biocompatible surfactant is selected from anionic surfactants and nonionic surfactants, or the biocompatible lipid is selected from phospholipids and paramagnetic lipids.

### Claim 34 (depends on 33)

The composition according to claim 33, wherein the biocompatible surfactant comprises polyethylene glycol or sodium dodecyl sulfate.

### Claim 35 (depends on 33)

The composition according to claim 33, wherein the MRI active agent comprises Fe3O4, Gd2O3, GdF3, NaGdF4, MnO, MnFe2O4, CoFe2O4, NiFe2O4, Fe, FePt, FeCo, FeO, Fe2O3 or combinations thereof.

### Claim 36 (depends on 30)

The composition according to claim 30, wherein the MRI active agent comprises Fe3O4, Gd2O3, GdF3, NaGdF4, MnO, MnFe2O4, CoFe2O4, NiFe2O4, Fe, FePt, FeCo, FeO, Fe2O3 or combinations thereof.

### Claim 37 (depends on 30)

The composition according to claim 30, wherein the composition further comprises a dopant selected from rubrene, iridium complexes, rare-earth materials and ZnS, ZnSe, ZnTe, InP, GaP, InGaP, and Mn doped ZnE semiconductor quantum dots, wherein E is selected from S, Se and Te.

### Claim 38 (depends on 30)

The composition according to claim 30, wherein the composition is encased in a layer of a biologically inert biocompatible material.

### Claim 39 (depends on 38)

The composition according to claim 38, wherein the biologically inert biocompatible material is silica, poly(methyl methacrylate), latex or polystyrene.

### Claim 40 (depends on 38)

The composition according to claim 38, comprising a layer of a further substantially water-insoluble conjugated polymer having a wider band gap than the substantially water-insoluble conjugated polymer between the substantially water-insoluble conjugated polymer and the biocompatible surfactant and/or lipid.

### Claim 41 (depends on 40)

The composition according to claim 40, wherein the further polymer is selected from poly(methyl methacrylate), polystyrene sulfonic acid, poly-N-alkylvinylpyridinium halogenide, poly (meth)acrylic acid, poly (amino acids), poly-N-vinylpyrrolidone, polyhydroxyethyl methacrylate, polyvinylether, polyethylene glycol, polypropylene oxide, and polysaccharides, and a combination or derivative thereof.

### Claim 42 (depends on 30)

The composition according to claim 30, wherein the biocompatible surfactant and/or lipid has been modified to selectively bind to a desired substance.

### Claim 43 (depends on 42)

The composition according to claim 42, wherein the biocompatible surfactant and/or lipid has been modified by the addition of a protein, nucleic acid, enzyme, antibody, an amine group, a carboxylic acid group, an alcohol-containing group, a thiol group, or biotin.

### Claim 44 (depends on 42)

The composition according to claim 42, wherein the substance is selected from drugs, metabolites, proteins, polypeptides, nucleic acids, cancer cells, organ tissue from a heart, liver or kidney, skin, blood or normal cells.

### Claim 45 (depends on 30)

The composition according to claim 30, wherein the composition is linked to a further species which exhibits luminescence or fluorescence within the wavelength band from about 300 nm to about 1500 nm of the electromagnetic spectrum.

### Claim 46 (depends on 45)

The composition according to claim 45, wherein the further species comprises a dye, a luminescent protein, or quantum dots selected from ZnS, ZnSe, ZnTe, InP, GaP, InGaP, and Mn doped Zn.

### Claim 47 (depends on 30)

A method of labelling a biological material, comprising the steps of: providing a composition according to claim 30; and bringing the composition into contact with the biological material.

### Claim 48 (depends on 47)

The method or use according to claim 47 wherein the labelling of a biological material is carried in vitro.

### Claim 49 (depends on 30)

The biological material labelled by a composition according to claim 30.

### Claim 50 (depends on 30)

A method for the detection of a substance, the method comprising:
providing a composition according to claim 30;
contacting the composition with the substance on a substrate; and
fluorescent and/or magnetic resonance imaging the composition to determine whether the substance was present on the substrate.

### Claim 51 (depends on 50)

The method of claim 50, and further comprising removing the composition from the substrate.

### Claim 52 (depends on 50)

The method according to claim 50, wherein the substance is a biological substance, drug, or metabolite.

### Claim 53 (depends on 50)

The method according to claim 50 wherein the substrate has a fingerprint of a human on a surface with which the particles are contacted.
